These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 37473958)

  • 1. KEAP1/NFE2L2 Pathway Signature Outperforms KEAP1/NFE2L2 Mutation Status and Reveals Alternative Pathway-Activating Mutations in NSCLC.
    Arolt C; Dugan M; Wild R; Richartz V; Holz B; Scheel AH; Brägelmann J; Wagener-Ryczek S; Merkelbach-Bruse S; Wolf J; Buettner R; Catanzariti L; Scheffler M; Hillmer AM
    J Thorac Oncol; 2023 Nov; 18(11):1550-1567. PubMed ID: 37473958
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of KEAP1/NFE2L2 Mutations in the Chemotherapeutic Response of Patients with Non-Small Cell Lung Cancer.
    Jeong Y; Hellyer JA; Stehr H; Hoang NT; Niu X; Das M; Padda SK; Ramchandran K; Neal JW; Wakelee H; Diehn M
    Clin Cancer Res; 2020 Jan; 26(1):274-281. PubMed ID: 31548347
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical and Pathological Characteristics of
    Frank R; Scheffler M; Merkelbach-Bruse S; Ihle MA; Kron A; Rauer M; Ueckeroth F; König K; Michels S; Fischer R; Eisert A; Fassunke J; Heydt C; Serke M; Ko YD; Gerigk U; Geist T; Kaminsky B; Heukamp LC; Clement-Ziza M; Büttner R; Wolf J
    Clin Cancer Res; 2018 Jul; 24(13):3087-3096. PubMed ID: 29615460
    [No Abstract]   [Full Text] [Related]  

  • 4. Mutations in the KEAP1-NFE2L2 Pathway Define a Molecular Subset of Rapidly Progressing Lung Adenocarcinoma.
    Goeman F; De Nicola F; Scalera S; Sperati F; Gallo E; Ciuffreda L; Pallocca M; Pizzuti L; Krasniqi E; Barchiesi G; Vici P; Barba M; Buglioni S; Casini B; Visca P; Pescarmona E; Mazzotta M; De Maria R; Fanciulli M; Ciliberto G; Maugeri-Saccà M
    J Thorac Oncol; 2019 Nov; 14(11):1924-1934. PubMed ID: 31323387
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of KEAP1/NFE2L2/CUL3 mutations on duration of response to EGFR tyrosine kinase inhibitors in EGFR mutated non-small cell lung cancer.
    Hellyer JA; Stehr H; Das M; Padda SK; Ramchandran K; Neal JW; Diehn M; Wakelee HA
    Lung Cancer; 2019 Aug; 134():42-45. PubMed ID: 31319993
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Survival Outcomes and Treatment Patterns in Patients With NFE2L2 and/or KEAP1 Mutation-Positive Advanced Squamous Cell NSCLC Using a Real-World Clinico-Genomic Database.
    Wu Y; Yin Y; Crossland V; Vincent S; Paik PK; Lineberry N; Faller DV
    Clin Lung Cancer; 2022 Sep; 23(6):487-497. PubMed ID: 35705448
    [TBL] [Abstract][Full Text] [Related]  

  • 7. NFE2L2/KEAP1 Mutations Correlate with Higher Tumor Mutational Burden Value/PD-L1 Expression and Potentiate Improved Clinical Outcome with Immunotherapy.
    Xu X; Yang Y; Liu X; Cao N; Zhang P; Zhao S; Chen D; Li L; He Y; Dong X; Wang K; Lin H; Mao N; Liu L
    Oncologist; 2020 Jun; 25(6):e955-e963. PubMed ID: 32272498
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical Implications of KEAP1-NFE2L2 Mutations in NSCLC.
    Hellyer JA; Padda SK; Diehn M; Wakelee HA
    J Thorac Oncol; 2021 Mar; 16(3):395-403. PubMed ID: 33307193
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting NFE2L2/KEAP1 Mutations in Advanced NSCLC With the TORC1/2 Inhibitor TAK-228.
    Paik PK; Fan PD; Qeriqi B; Namakydoust A; Daly B; Ahn L; Kim R; Plodkowski A; Ni A; Chang J; Fanaroff R; Ladanyi M; de Stanchina E; Rudin CM
    J Thorac Oncol; 2023 Apr; 18(4):516-526. PubMed ID: 36240971
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Loss of SWI/SNF Chromatin Remodeling Alters NRF2 Signaling in Non-Small Cell Lung Carcinoma.
    Song S; Nguyen V; Schrank T; Mulvaney K; Walter V; Wei D; Orvis T; Desai N; Zhang J; Hayes DN; Zheng Y; Major MB; Weissman BE
    Mol Cancer Res; 2020 Dec; 18(12):1777-1788. PubMed ID: 32855269
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Thioredoxin reductase-1 levels are associated with NRF2 pathway activation and tumor recurrence in non-small cell lung cancer.
    Delgobo M; Gonçalves RM; Delazeri MA; Falchetti M; Zandoná A; Nascimento das Neves R; Almeida K; Fagundes AC; Gelain DP; Fracasso JI; Macêdo GB; Priori L; Bassani N; Bishop AJR; Forcelini CM; Moreira JCF; Zanotto-Filho A
    Free Radic Biol Med; 2021 Dec; 177():58-71. PubMed ID: 34673143
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinicopathologic and Genomic Factors Impacting Efficacy of First-Line Chemoimmunotherapy in Advanced NSCLC.
    Alessi JV; Elkrief A; Ricciuti B; Wang X; Cortellini A; Vaz VR; Lamberti G; Frias RL; Venkatraman D; Fulgenzi CAM; Pecci F; Recondo G; Di Federico A; Barrichello A; Park H; Nishino M; Hambelton GM; Egger JV; Ladanyi M; Digumarthy S; Johnson BE; Christiani DC; Lin X; Gainor JF; Lin JJ; Pinato DJ; Schoenfeld AJ; Awad MM
    J Thorac Oncol; 2023 Jun; 18(6):731-743. PubMed ID: 36775193
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nrf2 and Keap1 abnormalities in non-small cell lung carcinoma and association with clinicopathologic features.
    Solis LM; Behrens C; Dong W; Suraokar M; Ozburn NC; Moran CA; Corvalan AH; Biswal S; Swisher SG; Bekele BN; Minna JD; Stewart DJ; Wistuba II
    Clin Cancer Res; 2010 Jul; 16(14):3743-53. PubMed ID: 20534738
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Transcriptomic Approach Outperforms Mutational Analysis to Identify KEAP1/NFE2L2 Pathway Activation in Patients With NSCLC.
    Hijazo-Pechero S; Muñoz-Pinedo C; Nadal E
    J Thorac Oncol; 2023 Nov; 18(11):1431-1433. PubMed ID: 37879763
    [No Abstract]   [Full Text] [Related]  

  • 15.
    Binkley MS; Jeon YJ; Nesselbush M; Moding EJ; Nabet BY; Almanza D; Kunder C; Stehr H; Yoo CH; Rhee S; Xiang M; Chabon JJ; Hamilton E; Kurtz DM; Gojenola L; Owen SG; Ko RB; Shin JH; Maxim PG; Lui NS; Backhus LM; Berry MF; Shrager JB; Ramchandran KJ; Padda SK; Das M; Neal JW; Wakelee HA; Alizadeh AA; Loo BW; Diehn M
    Cancer Discov; 2020 Dec; 10(12):1826-1841. PubMed ID: 33071215
    [TBL] [Abstract][Full Text] [Related]  

  • 16. KEAP1/NRF2 (NFE2L2) mutations in NSCLC - Fuel for a superresistant phenotype?
    Dempke WCM; Reck M
    Lung Cancer; 2021 Sep; 159():10-17. PubMed ID: 34303275
    [TBL] [Abstract][Full Text] [Related]  

  • 17. KEAP1-Mutant NSCLC: The Catastrophic Failure of a Cell-Protecting Hub.
    Scalera S; Mazzotta M; Cortile C; Krasniqi E; De Maria R; Cappuzzo F; Ciliberto G; Maugeri-Saccà M
    J Thorac Oncol; 2022 Jun; 17(6):751-757. PubMed ID: 35351670
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Impact of Durvalumab on Local-Regional Control in Stage III NSCLCs Treated With Chemoradiation and on KEAP1-NFE2L2-Mutant Tumors.
    Shaverdian N; Offin M; Shepherd AF; Simone CB; Gelblum DY; Wu AJ; Hellmann MD; Rimner A; Paik PK; Chaft JE; Gomez DR
    J Thorac Oncol; 2021 Aug; 16(8):1392-1402. PubMed ID: 33992811
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Integrated analysis of patients with KEAP1/NFE2L2/CUL3 mutations in lung adenocarcinomas.
    Jin X; Zheng Y; Chen Z; Wang F; Bi G; Li M; Liang J; Sui Q; Bian Y; Hu Z; Qiao Y; Xu S
    Cancer Med; 2021 Dec; 10(23):8673-8692. PubMed ID: 34617407
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular mechanisms for the regulation of Nrf2-mediated cell proliferation in non-small-cell lung cancers.
    Yamadori T; Ishii Y; Homma S; Morishima Y; Kurishima K; Itoh K; Yamamoto M; Minami Y; Noguchi M; Hizawa N
    Oncogene; 2012 Nov; 31(45):4768-77. PubMed ID: 22249257
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.